CN108048555A - A kind of kit for being used to detect osteoporosis - Google Patents
A kind of kit for being used to detect osteoporosis Download PDFInfo
- Publication number
- CN108048555A CN108048555A CN201810000235.9A CN201810000235A CN108048555A CN 108048555 A CN108048555 A CN 108048555A CN 201810000235 A CN201810000235 A CN 201810000235A CN 108048555 A CN108048555 A CN 108048555A
- Authority
- CN
- China
- Prior art keywords
- osteoporosis
- kit
- sample
- bone
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
For the present invention for detecting the kit of osteoporosis, the kit includes the probe and primer of energy specific detection rs10048745.Whether subject can be detected with osteoporosis by this kit, so as to which clinician be instructed to provide prevention scheme or therapeutic scheme to subject.And easy to operate, experimental method, it is of low cost.
Description
Technical field
The invention belongs to field of biological detection, in particular belong to a kind of kit for being used to detect osteoporosis.
Background technology
Osteoporosis, that is, osteoporosis, is one group of osteopathy caused by many reasons, and bone tissue has normal calcification, calcium salt
With matrix in normal rates, the metabolic bone disease with the characteristics of the reduction of unit volume inner bone tissues amount becomes.In most osteoporosises
In, caused by the reduction of bone tissue increases mainly due to bone absorption.By skeleton pain, be easy to fracture characterized by.
Clinical manifestation is pain, and the most common symptom of primary osteoporosis is common with lumbago, accounts in pain patients
70%~80%.Pain is lain on the back or pain relief during seat along backbone to two side diffusions, when upright after stretch or stand long, sitting
When the pain increased, bend over, cough, defecate firmly when aggravate.Ostalgia is may occur in which during general bone loss more than 12%.Old bone
During matter osteoporosis, Vertebral Compression deformation, flexion of vertebral column, muscular fatigue even spasm, generation pain.Recently Thoracolumbar disk compressibility bone
Folding, can also generate Acute Pain, the spinous process of corresponding site can have strong tenderness and percussion pain.If oppress corresponding spinal nerve
Four limbs Rediating Pain, double lower limb sensorimotor obstacle, intercostal neuralgia, retrosternal pain can be generated similar to angina pectoris.If oppress ridge
Marrow, cauda equina nerve have an effect on bladder, rectum function.The most common complication with most serious of degeneration osteoporosis.
The inspection of osteoporosis in the level of laboratory mainly it is following some:(1) blood calcium, phosphorus and alkaline phosphatase are in original
In hair property osteoporosis, serum calcium, phosphorus and alkaline phosphatase levels are typically normal, several months alkaline phosphatase after fracture
Level can increase.(2) blood parathyroid hormone should check secondary osteoporosis except parathyroid function.Primary sclerotin
Osteoporosis person's blood parathyroid hormone level can normally or rise.(3) the newer label patients with osteoporosis part-blood of bone
Clear biochemical indicator of learning can convert (including bon e formation and bone information) state with reactive bone, these Biochemistry measurement indexs include:Bone is special
Different alkaline phosphatase (reaction bon e formation), Tartrate resistant acid phosphatase (reaction bone information), osteocalcin (reaction bon e formation),
I type virgin rubber former peptide (reaction bon e formation), Pyridinoline and Deoxypyridinoline (reaction bone information), the N-C- ends of Type I collagen are handed over
Join peptide (reaction bone information).(4) urina sanguinis calcium/creatinine ratio normal ratio is 0.13 ± 0.01, and urinary calcium discharge capacity crosses at most ratio increasing
Height prompts have bone absorption rate that may increase.
Followed by auxiliary examination is divided into as the following aspects, 1. bone imageological examination and bone density absorb diseased region
X-ray film x-ray can be found that fracture and other lesions, such as osteoarthritis, disc disease and spondylolisthesis.Sclerotin is reduced
(low bone density), which takes the photograph visible bone bright degree during piece, to be increased, and bone trabecula is reduced and its gap is broadening, and row bone trabecula disappears, bone structure
It is fuzzy, but usually need to decline more than 30% just in bone amount it is observed that.Generally visible centrum concave-concave deformation, anterior margin of vertebral body collapse
Wedge shaped change, also known as compression fracture, are common in the 11st, 12 thoracic vertebraes and the 1st, 2 lumbar vertebraes.2. Bone mineral density Bone mineral density is
The prediction index of fracture.The bone density at what position is measured, can be used for assessing overall fracture degree of causing danger;Measure particular portion
The bone density of position can predict the danger that local fracture occurs.
In the prior art, it is close by detection and osteoporosis generation to disclose a kind of kit by 102534019 A of CN
Cut relevant 5 mononucleotide polymorphism sites genotype come examination go out easily suffer from osteoporosis women people at highest risk,
And finally according to the genetic test result of each person under inspection from the susceptible risk class of gene level assessment osteoporosis, refer to
Lead the climacteric women targetedly effectively generation of pre- anti-osteoporosis.
106755522 A of CN disclose a kind of kit for the detection of juvenile form osteoporosis, are compared by gene
It was found that DKK1 genes are 721 sites there is apparent mutational site in juvenile form sufferers of osteoporosis face and normal population.It is logical
Cross and detect this mutational site, 1 be especially to provide pair specific primer pair, can specificity identification human body when with children
Model year osteoporosis symptoms.The detection method has easy to detect, quickly and accurately advantage compared with the method for the prior art, fits
It is suitable for and promotes the use of.
107043811 A of CN disclose the molecular marker that CFAP20 genes can be early diagnosed as osteoporosis.
Utilize the difference expression gene in high-flux sequence and QPCR experimental studies patients with osteoporosis.The achievement in research shows can
To judge subject whether with osteoporosis by detecting in blood CFAP20 expression conditions.
Based on the limitation for the means for detecting osteoporosis in the prior art, osteoporosis early diagnosis and prognosis are found
Relevant specificity molecular marker has far reaching significance to the early diagnosis and individualized treatment of realizing osteoporosis.
The content of the invention
The present invention provides for detecting the kit of rs10048745 genotype, testing result can be used in osteoporosis
The assistant analysis of disease.
First purpose of the present invention is to provide the kit for detecting gene SNP site rs10048745 genotype,
The kit includes primer pair and PCR detection reaction reagents.
Kit according to the invention can provide the side that a kind of osteoporosis neurological susceptibility to individual is diagnosed
Method, this method are:The polymorphism status in the rs10048745 sites of individual is detected, low bone density is not shown when site is G
Characteristic, when mutated-genotype A results in the reduction of bone density value, so as to ultimately result in the generation of osteoporosis.
The present invention provides a kind of detect in sample to include such as with the presence or absence of the method for rs10048745 polymorphisms, this method
Lower step:(1) using our self-designed kit amplified samples, pcr amplification product is obtained.
The present invention is detected using TAQMAN technologies whether there is single nucleotide polymorphism in amplified production.The present invention's is basic
Technology path is:A kind of method for identifying SNP marker in rs10048745 polymorphisms, by the genome for extracting sample
DNA is carried out PCR amplification using kit provided by the invention, expands target fragment, be detected using TAQMAN technologies, sent out
Existing SNP exists, and the presence of the SNP and existing position are confirmed using DNA sequencing method.
The detection fragment sequence in rs10048745 sites such as SEQ ID NO:Shown in 1.Length is 201bp, and particular sequence is such as
Under:atttctggta aaactgaaag caagaaaagc agggtgctag cccctgtggg actgagggtg
gaggctgggg gagtttgggt gccatcctcc agtgacagat ggatggacctt tcatctaaga gaaaggagga
gacacgttgg caaatcagcc tcaagcctaa gattgcttgt gaagcaatca taaggaggaa caaaaacaga
Those skilled in the art is aware that have many analysis methods to can be used in detection gene intron sequence existing
Single nucleotide polymorphism distribution frequency.These technologies include:DNA sequencing, PCR-SSCP, PCR-HPLC, PCR-TAQMAN etc..
Present invention especially provides a kind of detection kits of the above-mentioned SNP of detection easy to use, high sensitivity, it contains
There are PCR specific amplification primers and the PCR reaction solution (such as reagent, buffer solution general components) for PCR amplification detection etc., ability
These known general components of field technique personnel and detection method.Using TAQMAN technologies detection amplified production detection mutation position
Point, it is also necessary to some required conventional reagents of TAQMAN etc..
Specifically, the present invention provides a kind of PCR kit for the SNP for detecting rs10048745, it is characterized in that by drawing
Object 1, primer 2, probe 3, probe 4 and PCR reaction solution are formed, wherein, the 5' ends of the probe 3 and probe 4 are marked with report base
Group, 3' ends are marked with fluorescent quenching group, and the 5' ends reporter group of probe 4 is different from the 5' ends reporter group of probe 3.
Wherein, the reporter group of 5' ends mark may be selected from:FAM、HEX、TET、JOE、VIC、R0X、Cy3、Cy5、MAR、
JUP, SAT, PLU or NEP, and it is not limited to above-mentioned group;The fluorescent quenching group of 3' ends mark may be selected from:TAMRA、Eclipse、
BHQ1, BHQ2, BHQ3, DABCYL, MGB, and it is not limited to above-mentioned group.
Preferably, the reporter group of 5' ends mark is FAM or the fluorescent quenching group of VIC, 3' end mark is MGB.
PCR amplification:Used amplimer sequence is:
Forward primer 1:atttctggta aaactgaaag;
Reverse primer 2:tctgtttttg ttcctcctta;
Specific probe sequence 3:Agtgacagat a gatggacctt, wherein 5 ' section of sequence are marked using FAM, and 3 ' ends are used
MGB is marked,
Specific probe sequence 4:Agtgacagat g gatggacctt, wherein 5 ' section of sequence are marked using VIC, and 3 ' ends are used
MGB is marked.
The advantages of the present invention:
Present invention firstly discovers that rs10048745 polymorphisms are related to osteoporosis, by detecting in subject
The polymorphic implementations of rs10048745, it can be determined that subject whether with osteoporosis, so as to instruct clinician to by
Examination person provides prevention scheme or therapeutic scheme.And easy to operate, experimental method, it is of low cost.
Specific embodiment
With reference to specific embodiment, the present invention is further explained.It is to be understood that these embodiments are merely to illustrate the present invention
Rather than it limits the scope of the invention.The experimental method of actual conditions is not specified in the following example or according to manufacturer
Proposed condition.Unless otherwise stated, otherwise percentage and number are calculated by weight.
Unless otherwise defined, all professional and scientific terms used in text and meaning known to one skilled in the art
Justice is identical.In addition, any method similar or impartial to described content and material all can be applied in the present invention.It is described in text
Preferred implement methods and materials be for illustrative purposes only.
The acquisition of 1 SNP marker of embodiment
Research sample is obtained from multiple researchs and medical center.All researchs passed the examination & approval of Ethics Committee, and
Obtain the informed consent of research object.We are to from six different blood lineages having a lumbar vertebrae and femoral neck bone density value measures
Sample has carried out full-length genome correlation analysis (GWAS), and merging data carries out meta analyses.In addition, we also have collected
The meta analysis results of European descent crowd lumbar vertebrae and femoral neck bone density in GEFOS-seq public databases, and by two
Divided data, which merges, carries out Conjoint Analysis so that association results are mutually authenticated.
First portion internal specimen meta is analyzed
1st, the selection of sample
Meta points of GWAS is carried out in the sample that we at seven there is lumbar vertebrae and femoral neck bone density value to measure early period
Analysis.Wherein, Yin Fulei Framinghams heart disease research (FHS) sample is overlapped with GEFOS-seq samples, in order to ensure two parts sample
Independence, we reject FHS samples from internal specimen.Remaining six sample essential informations are as follows:
(1) Omaha osteoporosises research sample (OOS):It grinds in the cross section that OOS samples include 1000 random participants
Study carefully.
(2) Kansas City osteoporosis research sample (KCOS):KCOS samples include the horizontal stroke of 2286 random participants
Section is studied.
(3) state of Indiana fragility fractures research sample (IFS):IFS samples are obtained by dbGAP databases, bag
Cross-sectional study of the premenopausal sister to participant of 1493 European descents is included.
(4) Chinese osteoporosis research sample (COS):COS samples include the cross section of 1627 random participants
Research.
(5) the non-preliminary observational study of descendants American's women's health (WHI-AA):WHI-AA samples are that women's health is tentatively seen
A part for research (WHI) is surveyed, 845 non-descendants American participants is contained, can be obtained by dbGAP databases.
(6) the preliminary observational study of Hispanic women's health (WHI-HIS):WHI-HIS samples are also a part of WHI,
446 Hispanic participants are contained, can be obtained by dbGAP databases.
2nd, phenotype measurement and modeling
Bone density value is measured by DXA borne densitometers.Use stepping Return Law examination gender, age, age square, height
And the conspicuousness of the covariants such as preceding 10 principal components (for weighing population layering effect) calculated from genomic data.It is former
Residual error of the beginning bone density value after covariant corrects carrys out normal state using the quantile of normal distribution.Residual error after normal state is used
It is analyzed in downstream associative.
3rd, Genotyping and Quality Control
All six samples use high-throughput gene typing chips parting.Quality Control is realized in sample level and SNP levels.
In sample level, infer gender using plink softwares analysis X chromosome, and compared with the gender in questionnaire.Gender
The individual not being inconsistent is deleted from data.In SNP levels, the SNP for not meeting Ha-temperature balance is deleted from data.When there are crowds
During extremum, the genotype of principal component is checked, and reject extremum.
4th, genotype is filled a vacancy
Genotype is carried out using the sequencing data (in May, 2013 version) of thousand human genomes to all samples to fill a vacancy.First,
Haplotype data (503 people of European descent, the East Asia blood lineage 504 of the sequencing individual of 4 class ethnic groups are downloaded from thousand human genome websites
347 people of people, 661 people of African descent and mixing American blood lineage), respectively mould is referred to as the Genotyping of respective sample
Plate.Secondly, one is done to the allele of reference gene group (i.e. thousand human genome data) and target gene group (i.e. GWAS samples)
Cause property is examined, and examines the person of not being inconsistent that will be deleted from target gene group.Finally, carry out genotype using software FISH to fill a vacancy, this
Algorithm has the advantages that arithmetic speed is fast, and committed memory is small, without shifting to an earlier date split-phase (phasing) to target gene group.Software is joined
Number default setting.
5th, the association analysis in single sample and meta analyses
In each sample, the genetic association between the phenotype residual sum parting of normal state and the genotype filled a vacancy out passes through something lost
Cumulative model is passed to examine.In unrelated sample, genetic association is examined using linear regression model (LRM), software MACH2QTL.It is right
In IFS family samples, then using the degree of association of mixed linear model calculating genotype.The association results of six samples merge one
It rises and carries out meta analyses.Model used is the fixed-effect model of sample size weighting, and software used is METAL.
The collection of second portion GEFOS-seq meta analysis results
GEFOS-seq researchs are organized in has carried out sequencing and genotype is filled a vacancy in more than 50,000 European descent participants
Based on bone density GWAS meta analysis.Sample information, Quality Control and statistical analysis refer to GEFOS-seq official websites.In short
It, this research includes three parts content:1st, 2,882 research objects in studying UK10K carry out genome sequencing;2nd, it is right
3,549 research objects in 5 cohort studies carry out genome sequencing;3rd, full genome is carried out to 26,534 research objects
Group genotype is filled a vacancy.All samples have all carried out meta analyses, and partial results external disclosure.Here, we pass through
GEFOS-seq has downloaded official website the meta analysis results that this part sample size is up to 32,965.
SNP inclusion criterias
For the meta analysis results of six internal specimens of first portion, the quality control standard that the SNP that we take is included is:
Allelic heterogeneity I2<50%.For second portion GEFOS-seq meta analysis results, what we took includes quality control standard then
For:1. allelic heterogeneity I2<50%;2. minimum gene frequency (MAF)>1%.For meeting two parts Quality Control
SNPs, we are included in research in next step.
Conjoint Analysis
By the meta analysis results of two parts sample, we have respectively obtained two parts z values:z1And z2.Then, Wo Menyun
Conjoint Analysis is carried out with weighting fixed effect meta analysis models, formula is as follows:
In formula, n1And n2Refer to the sample size of internal specimen and GEFOS-seq samples respectively.In the case where null hypothesis is set up,
When i.e. there is no associating, statistical value Z Normal Distributions or approximate normal distribution.The GWAS levels of signifiance are set to 5.0x10-8。
Conclusion
In internal specimen research, 7,484 research objects are covered altogether.It is not examined using principal component analysis in each sample
Go out heterogeneous individual.After PCA correction population layerings, lumbar vertebrae and the femoral neck bone density genome coefficient of expansion are 1.03 respectively
With 1.02, less than warning value, illustrate no apparent population layering effect.In GEFOS-seq meta analysis results, one is shared
32,965 research objects cover 10,586,901 SNPs, and after Quality Control screens out, one shares 7,434,754 SNPs
It is included into the Conjoint Analysis of next step.
Two-part Conjoint Analysis is found that many and lumbar vertebrae and the relevant site of femoral neck bone density.Some sites are not only
Reach the full-length genome level of signifiance (GWS, p in GEFOS-seq samples<5.0x10-8), it is also repeated in internal specimen
Verify (p<0.05).Furthermore it has been found that reach the new site of the full-length genome level of signifiance:2p13.3
(rs10048745, p=3.94x10-8)。
SNP rs10048745 and associating for lumbar spine bmd on the site is the most notable (it was found that sample p1=
0.02, GEFOS-seq sample p2=1.03x10-6, merge sample p12=3.94x10-8).Detailed results such as the following table 1:
Table 1rs10048745 result datas
It can be seen that from the data of table 1 for rs10048745 sites, there are the mutation of A/G, when it is A, table
It is now low bone density characteristic, low bone density characteristic is not shown when it is G.Mutated-genotype A results in the drop of bone density value
Low, so as to ultimately result in the generation of osteoporosis, this rise is statistically extreme significant (p=3.94x10-8),
Therefore osteoporosis can be detected by detecting the loci gene type.
2 specific pattern detection of embodiment
1. study the selection of sample;
Patients with osteoporosis blood sample sample used in the present invention come from First Affiliated Hospital of Soochow University,Suzhou, totally 100
Patient diagnosed's sample.The inclusion criteria for studying sample is as follows:Age is the women of 18-70 Sui;It is examined through Bone mineral density and X-ray
Survey is made a definite diagnosis;Dysfunction without main organs, blood routine, hepatic and renal function and cardiac function are normal;Can obtain completely with
Visit information.All research objects are the Chinese Han Population of consanguinity-less relation, geographically essentially from East China and its surrounding area.With
100 normal population blood are control.Sufferer is included to above-mentioned, compiles its essential information, clinical information and treatment letter
Breath, and sign informed consent form according to Principles in Informed Consent.
2. the extracting of genomic DNA;
Sample centrifuges serum and blood using the peripheric venous blood 2ml of the heparin tube collection research object of EDTA anti-freezings
- 80 DEG C of refrigerators are stored in after cell.Using the centrifugal adsorbing column that can specifically bind DNA and unique buffer system, extraction
Peripheral blood genomic DNA, operates according to a conventional method.Usually lead to 50ng DNA, purity (ultraviolet 2600D:2800D) 1.8
Left and right.
3rd, PCR amplification system is prepared:
And SEQ ID NO are separately added into each DNA:The mixed liquor of primer and probe shown in 2-5 is cooked PCR reactions, is come
Parting is carried out to each SNP respectively, required reagent includes Taqman Genotyping Master Mix5 μ l, ddH20 3.5μ
1st, 0.5 μ l of fluorescence probe and primer mixed liquor, remaining is the 1 μ l of examinate's DNA sample, 10 μ l of total volume of 50ng/ μ l.
4th, PCR amplification program:
PCR reacts the first step:60℃、35s;PCR reacts second step:96℃、10min;PCR reacts the 3rd step:93℃、
20s;PCR reacts the 4th step:60℃、95s;PCR reacts the 5th step:Cycle the 4th step of the 3rd step 5 times, then 60 DEG C, 25s.It adopts
It is dashed forward Fluorescent Quantitative PCR instrument (Applied Biosystems, Applied Biotechnology Co., Ltd of the U.S.) with ABI Stepone.
5th, experimental result:
PCR after reaction, is analyzed using Stepone software V2.1, and obtain 200 results are carried out
Classification, probe according to the invention, which is divided into, discerns 3 kinds of genotype:Tri- kinds of frequency of genotypes AA of SNP rs10048745, GG and AG.
6th, the analysis of the accuracy of kit
For the accuracy of verification kit detection, sequence verification is carried out to 200 samples.SNP rs10048745 genotype
GG has 189, and AG genotype has 10, and AA genotype has 1;Wherein AG genotype and AA genotype are that osteoporosis is suffered from
Person, therefore the accuracy of kit detection has reached 100%.
The value of this kit is only to need peripheral blood without other tissue samples, by most simplifying and special
Amplimer detects SNP site, then composes evaluation patient profiles by SNP, not only stablizes, easy to detect and accurate, greatly improves
The sensibility and specificity of medical diagnosis on disease, therefore this kit is put into and is put into practice, can help to instruct people at highest risk screening and
More effective individualized treatment.
Specific embodiments of the present invention are described in detail above, but it is only used as example, and the present invention is not intended to limit
In particular embodiments described above.To those skilled in the art, it is any to the equivalent modifications that carry out of the present invention and to replace
In generation, is also all among scope of the invention.Therefore, the impartial conversion made without departing from the spirit and scope of the invention and repair
Change, all should be contained within the scope of the invention.
Sequence table
<110>Beijing Yue Hao developments in science and technology Co., Ltd
<120>A kind of kit for being used to detect osteoporosis
<160> 5
<170> SIPOSequenceListing 1.0
<210> 1
<211> 201
<212> DNA
<213>People (Homo sapiens)
<400> 1
atttctggta aaactgaaag caagaaaagc agggtgctag cccctgtggg actgagggtg 60
gaggctgggg gagtttgggt gccatcctcc agtgacagat ggatggacct ttcatctaag 120
agaaaggagg agacacgttg gcaaatcagc ctcaagccta agattgcttg tgaagcaatc 180
ataaggagga acaaaaacag a 201
<210> 2
<211> 20
<212> DNA
<213>Artificial sequence (Homo sapiens)
<400> 2
atttctggta aaactgaaag 20
<210> 3
<211> 20
<212> DNA
<213>Artificial sequence (Homo sapiens)
<400> 3
tctgtttttg ttcctcctta 20
<210> 4
<211> 21
<212> DNA
<213>Artificial sequence (Homo sapiens)
<400> 4
agtgacagat agatggacct t 21
<210> 5
<211> 21
<212> DNA
<213>Artificial sequence (Homo sapiens)
<400> 5
agtgacagat ggatggacct t 21
Claims (6)
1. a kind of kit for being used to detect osteoporosis, it is characterised in that:The kit includes can specific detection
The probe and primer of rs10048745.
2. kit as claimed in claim 2, it is characterised in that:The kit includes SEQ ID NO:Described in 2-5
Primer sets and probe sequence.
3. SEQ ID NO:Primer sets and probe sequence described in 2-5 are in the kit for osteoporosis detection is prepared
Application.
4. purposes of the rs10048745 as the target spot of detection osteoporosis.
5. rs10048745 is being prepared for the application in the kit of osteoporosis detection.
6. a kind of method for detecting osteoporosis, includes the use of claim 1-2 any one of them kits.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810000235.9A CN108048555B (en) | 2018-01-01 | 2018-01-01 | Kit for detecting osteoporosis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810000235.9A CN108048555B (en) | 2018-01-01 | 2018-01-01 | Kit for detecting osteoporosis |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108048555A true CN108048555A (en) | 2018-05-18 |
CN108048555B CN108048555B (en) | 2019-12-06 |
Family
ID=62126121
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810000235.9A Expired - Fee Related CN108048555B (en) | 2018-01-01 | 2018-01-01 | Kit for detecting osteoporosis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108048555B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106755522A (en) * | 2017-02-20 | 2017-05-31 | 苏州大学 | A kind of kit for the detection of juvenile form osteoporosis |
CN106868125A (en) * | 2017-02-20 | 2017-06-20 | 苏州大学 | For the kit of juvenile form osteoporosis detection |
-
2018
- 2018-01-01 CN CN201810000235.9A patent/CN108048555B/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106755522A (en) * | 2017-02-20 | 2017-05-31 | 苏州大学 | A kind of kit for the detection of juvenile form osteoporosis |
CN106868125A (en) * | 2017-02-20 | 2017-06-20 | 苏州大学 | For the kit of juvenile form osteoporosis detection |
Non-Patent Citations (1)
Title |
---|
WI_SSAHASNP: "GenBank Accession: NT_022184", 《DBSNP》 * |
Also Published As
Publication number | Publication date |
---|---|
CN108048555B (en) | 2019-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103205488B (en) | Method and reagent for prediction of ankylosing spondylitis susceptibility | |
CN105256039A (en) | Osteoporosis diagnosis marker | |
CN110277138A (en) | A kind of steroid femur head necrosis tumor susceptibility gene detection model | |
CN108220426B (en) | It is a kind of for detecting the kit of osteoporosis | |
CN107988359B (en) | It is a kind of for detecting the kit of osteoporosis | |
CN108048556B (en) | It is a kind of for detecting the kit of osteoporosis | |
CN108220425B (en) | It is a kind of for detecting the kit of osteoporosis | |
CN107988360B (en) | It is a kind of for detecting the kit of osteoporosis | |
CN107937518B (en) | It is a kind of for detecting the kit of osteoporosis | |
CN108048558B (en) | It is a kind of for detecting the kit of osteoporosis | |
CN108048555A (en) | A kind of kit for being used to detect osteoporosis | |
CN108034715A (en) | A kind of kit for being used to detect osteoporosis | |
CN107937517A (en) | A kind of kit for being used to detect osteoporosis | |
CN103710447B (en) | Method and reagent for predicting susceptibility of ankylosing spondylitis | |
CN112824537A (en) | Kit for specifically detecting sarcopenia through rs524533 | |
CN106834459B (en) | It is a kind of by detect rs6046310 come the kit of specific detection obesity | |
CN103882112B (en) | A kind of reagent and method predicting susceptibility of ankylosing spondylitis | |
CN103695549B (en) | Agent for predicting susceptibility to ankylosing spondylitis | |
CN107058497A (en) | It is a kind of by detecting rs16981092 come the kit of specific detection obesity | |
CN112824538A (en) | Kit for specifically detecting sarcopenia through rs551145 | |
CN112824536A (en) | Kit for specifically detecting sarcopenia through rs545970 | |
CN103725781B (en) | Kit and method for predicting susceptibility of ankylosing spondylitis | |
CN106591476A (en) | Kit for specifically detecting obesity by detecting rs2069126 | |
CN112824539A (en) | Kit for specifically detecting sarcopenia through rs571770 | |
CN109055542A (en) | Predict the method and DNA methylation marker of weightless bone loss lumbar spine bmd downside risk |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190902 Address after: 065000 No. 8, No. 3 Road, Langfang Economic and Technological Development Zone, Hebei Province Applicant after: Langfang Norway Medical Laboratory Co.,Ltd. Address before: No. 4315, 4th Floor, Building 7, Fengxian Middle Road, Haidian District, Beijing, 100000 Applicant before: BEIJING YUEHAO TECHNOLOGY DEVELOPMENT CO.,LTD. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20191206 Termination date: 20220101 |
|
CF01 | Termination of patent right due to non-payment of annual fee |